All News

At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.

Cancer can give writers a special edge.

The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

As we survive cancer, people often turn to us for advice. Listening mindfully as we also share personal tips can help others in their cancer journeys. The list of tips can only grow from survivor to survivor. What do you have to share?

These discussions should include information about the cancer itself, as well as treatment options, side effects, prognosis, and most importantly, the patient’s values.

Four ways of helping cancer survivors deal with anxiety and depression.

A no-brainer bill about student loans for young adult cancer patients that I spent a day advocating for. You can help - read to the end!

Fear of cancer recurrence is a common issues survivors face. The struggle is real to keep it in its proper place. Read how one survivor sees the struggle.

Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.

While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.

The FDA has accepted a supplemental biologics license application (sBLA) for the use of Keytruda (pembrolizumab) as an adjuvant treatment for patients with resected, high-risk stage 3 melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.

The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

An IBC patient reflects on her search for an alternative to conventional treatment.

There can be definite struggles for childhood cancer survivors, even many years later.

A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.

Palliative care doesn't mean giving up treatment, it means getting the support you need as a patient with metastatic cancer.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

What to do when cancer isn't ruining your summer...

Part three in a three part series about my trip to Chicago for HealtheVoices 2018.

This year’s survey is expanded to better learn about the experience of caregivers, with a selection of questions specifically for them. The Alliance asks that just one caregiver per patient fill out the survey.

Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.

The American Society of Clinical Oncology issued guidelines in 2017 to support the use of meditation, yoga, acupuncture and music therapy among to help relieve side effects from cancer treatment.

CURE spoke with the chief medical officer of the Leukemia & Lymphoma Society to hear what she thinks are important next steps in improving patient outcomes.

An MPN diagnosis can be overwhelming, but here are some of the basic facts every newly diagnosed patient should know.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

Sometimes the people who inspire us are closer than we realize.

The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds